Cancer Chemotherapy and Pharmacology

, Volume 20, Issue 3, pp 219–222

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients

  • Garth Powis
  • Phillip Reece
  • David L. Ahmann
  • James N. Ingle
Original Articles Cyclophosphamide, Pharmacokinetics, Breast Cancer

DOI: 10.1007/BF00570489

Cite this article as:
Powis, G., Reece, P., Ahmann, D.L. et al. Cancer Chemother. Pharmacol. (1987) 20: 219. doi:10.1007/BF00570489

Summary

Cyclophosphamide pharmacolinetics have been studied in 16 female patients with advanced breast cancer. The group included 7 patients who were >20%, ≤30% over ideal body weight and 5 patients who were >30% over ideal body weight. Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.31 (mean 36.11), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min). There was a significant positive correlation (r=0.624,P=0.010) between body weight and plasma elimination half-life, and a significant negative correlation between body weight and cyclophosphamide clearance when normalized to body surface area (r=0.578,P=0.019) or normalized to ideal body weight (r=0.531,P=0.0345). the apparent volume of distribution did not correlate with body weight. The results show that cyclophosphamide disposition is altered in patients with increased body weight.

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Garth Powis
    • 1
  • Phillip Reece
    • 2
  • David L. Ahmann
    • 2
  • James N. Ingle
    • 2
  1. 1.Department of PharmacologyMayo Clinic & FoundationRochesterUSA
  2. 2.Department of OncologyMayo Clinic & FoundationRochesterUSA
  3. 3.Department of Clinical PharmacologyQueen Elizabeth HospitalWoodvilleAustralia